IACAPAP 2012 – 20th World congress / Neuropsychiatrie de l’enfance et de l’adolescence 60S (2012) S254–S309 Information Processing (RVIP), Reaction Time (RT), Matching to Sample Visual Searching (MSVS), Delayed Matching to Sample (DMS), Spatial Recognition Memory (SRM), Paired Associates Learning (PAL), Pattern Recognition Memory (PRM) of the CANTAB. Compared with non-ADHD controls, the ADHD-C and ADHD-I groups had poorer performance in sustained attention (RVIP), slower response speed (RT), poorer visual memory (MSVS and PAL), poorer recognition memory (DMS, SRM, and PRM) after controlling for sex, age, IQ, and comorbidity. The findings suggest that attention and visual memory deficits in ADHD are mainly associated with inattention symptoms. http://dx.doi.org/10.1016/j.neurenf.2012.04.684 We-P-3041
Psychiatric-related safety outcomes of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: A phase 3, randomized, double-blind, multicentre, parallel-group, placebo- and active-controlled, dose-optimized study in Europe M.L. Lecendreux a,∗ , R.W. Dittmann b , M. Gasior c , T. Banaschewski d , R. Civil c , R. Bloomfield e , L. Squires c , D.R. Coghill f a CHU-Hospital Robert-Debré, Pediatric Sleep Centre, Paris, France b Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany c Shire Development LLC, Wayne, USA d Child and Adolescent Psychiatry and Psychotherapy, Central Institute Of Mental Health, University of Heidelberg, Mannheim, Germany e Shire Pharmaceutical Development Ltd, Basingstoke, UK f Division Of Neuroscience, Ninewells Hospital, Dundee, UK ∗ Corresponding author. Subjects (6–17 years) with ADHD were randomized to lisdexamfetamine dimesylate (LDX), placebo or extended-release methylphenidate (OROS-MPH; reference arm) over 7 weeks. Responses to the Brief Psychiatric Rating Scale for Children (BPRS-C) and Columbia-Suicide Severity Rating Scale (C-SSRS) were monitored. 196/336 subjects completed the study. BPRS-C scores at baseline were similar for all groups (mean ± SD: LDX, 20.5 ± 10.3; placebo, 21.1 ± 14.7; OROS-MPH, 23.8 ± 15.2). BPRS-C scores decreased from baseline (improvement) to study endpoint (mean change from baseline ±SD: LDX, –9.2 ± 11.3; placebo,–2.6 ± 7.4; OROS-MPH,–9.7 ± 6.9). One subject treated with OROS-MPH reported a suicidal ideation on the BPRS-C. On the C-SSRS, two subjects treated with LDX reported suicidal behaviour or ideation; no other subjects answered ‘yes’ to any item of the C-SSRS while on treatment. These results are consistent with the well-documented safety profiles of LDX and OROS-MPH. Supported by funding from Shire Development LLC. http://dx.doi.org/10.1016/j.neurenf.2012.04.685 We-P-3042
Weight-related safety outcomes of lisdexamfetamine dimesylate in children and adolescents with ADHD: Post-hoc analysis from a phase 3, randomized, double-blind, multicentre, parallel-group, placebo- and active-controlled, dose-optimized study in Europe A. Zuddas a,∗ , D.R. Coghill b , T. Banaschewski c , C. Soutullo d , A. Lynes e , P. Hodgkins f , M. Gasior f a Centre for Pharmacological Therapies in Children and Adolescent Neuropsychiatry, University of Cagliari, Cagliari, Italy b Division of Neuroscience, Ninewells Hospital, Dundee, UK c Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany d Child and Adolescent Psychiatry Unit, Department Of Psychiatry and Medical Psychology, University Clinic of Navarra, Pamplona, Spain e Shire Pharmaceutical Development Ltd, Basingstoke, UK f Shire Development LLC, Wayne, USA ∗ Corresponding author.
S263
Children (6–12 years) and adolescents (13–17 years) with ADHD were randomized to lisdexamfetamine dimesylate (LDX), placebo or extended-release methylphenidate (OROS-MPH; reference arm) over 7 weeks. 332/336 subjects were included in the safety population. Baseline weight and BMI were similar across groups. At endpoint, weight (mean ± SD kg) decreased with LDX (children: –1.7 ± 1.5; adolescents: –3.0 ± 2.5) and OROS-MPH (children: –1.4 ± 1.2; adolescents: –1.1 ± 2.0), but not placebo (children: 0.6 ± 0.9; adolescents: 1.2 ± 1.2). Most subjects remained in their baseline BMI category (underweight, healthy weight, risk of overweight, overweight) during study. Most BMI shifts occurred within healthy weight and risk of overweight categories. Seven children (LDX, 4; OROS-MPH, 3) and 3 adolescents (LDX, 2; OROS-MPH, 1) shifted from healthy weight to underweight by endpoint. A slight mean weight loss occurred in LDX- and OROS-MPH-treated patients consistent with the known effect of stimulants; future studies will examine extended LDX treatment. Supported by funding from Shire Development LLC. http://dx.doi.org/10.1016/j.neurenf.2012.04.686 We-P-3043
Children with ADHD: Psychiatric comorbidity A. Kesic a,∗ , A. Lakic b a Child Psychiatry, Child and Adolescent Neurology and Psychiatry Clinic, Belgrade, Serbia b Child and Adolescent Neurology and Psychiatry Clinic, School of Medicine, University of Belgrade, Belgrade, Serbia ∗ Corresponding author. Introduction.– Attention deficit hyperactivity disorder (ADHD) is one of the most common childhood psychiatric disorders, affecting 3% to 5% of school-age children. Children with ADHD often have other psychiatric disorders. Methods.– We examined 40 elementary school-age children with ADHD, according to DSM IV criteria. Results.– In our study, among children with ADHD we found that 71% have comorbid psychiatric disorder. Most of them (40.2%) have ODD. Distribution of other comorbid psychiatric disorders is as follows: 22% have CD, 25% have an affective or anxiety disorders. The other children from our sample have different but not consistent psychiatric symptoms. For all these children with ADHD and comorbid psychiatric disorders school performance is significantly worse compared to no comorbid disorders. Conclusion.– Comorbidity greatly influences diagnosis, presentation and prognosis, and before all notably makes treatment difficult. http://dx.doi.org/10.1016/j.neurenf.2012.04.687 We-P-3044
Suicidal and self-harm behaviour associated with adolescent attention deficit hyperactivity disorder: A study in the northern Finland birth cohort 1986 T. Hurtig a,∗ , A. Taanila a , I. Moilanen b , T. Nordström a , H. Ebeling b Institute of Health Sciences, University of Oulu, University of Oulu, Finland b Clinic of Child Psychiatry, University of Oulu, University of Oulu, Finland ∗ Corresponding author.
a
Suicidal behaviour, i.e. suicidal ideation and suicidal acts, as well as self-harm behaviour are relatively common among adolescents with whom depression and/or female gender seem to be risk factors. However, the role of Attention Deficit Hyperactivity Disorder (ADHD) in these behaviours is still unclear. We aimed to study the independent effect of ADHD on suicidal or self-harm behaviour in adolescents from a general population sample (Northern Finland Birth Cohort 1986, n = 9432). Based on Kiddie-SADS-PL interview performed in a subpopulation (n = 457), the associations between suicidal behaviour and deliberate self-harm (DSH) and ADHD were studied. Compared to adolescents without ADHD (n = 169), those with ADHD (n = 104) had more suicidal ideation, suicidal acts, and DSH. In binary logistic models the effect of ADHD on suicidal ideation remained strong (OR varied from 4.1 to 6.1) after controlling for several other predictors. Other contributing factors in suicidal behaviour included female gender, childhood emotional and behavioural problems, concurrent depression and anxiety, and, specifically in DSH, behavioural disorder, substance abuse and